262351 Collaborative Drug Therapy Management Policies: Strengthening the Role of Pharmacists in Team-based Care for Prevention and Management of Chronic Disease

Tuesday, October 30, 2012

Benjamin Bluml, RPh , Vice President, Research, American Pharmacists Association Foundation, Washington, DC
Siobhan Gilchrist, JD, MPH , Columbus Technologies and Services, Inc., Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, Atlanta, GA
Lindsay Watson, PharmD, RPh , Project Management Specialist, American Pharmacists Association Foundation, Washington
Dyann Matson Koffman, DrPH, MPH, CHES , Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, Atlanta, GA
Pharmacist engagement in interdisciplinary health management with physicians and other providers can significantly improve patients' health. Collaborative drug therapy management (CDTM) is one of the main components of team-based care that shows promise for preventing and managing chronic disease. It includes a formal agreement between pharmacists, physicians, and other health care providers in which the pharmacist provides patient care following an agreed upon protocol. CDTM may include initiating, discontinuing, and adjusting a medication dosage or type and communicating with the provider and patient about the patient's health status, medications, adverse reactions, and other information. States typically regulate CDTM through scope of practice acts and Boards of Pharmacy and Medicine regulations. There are over 60,000 community-based pharmacies employing over 175,000 pharmacists across the US. By enacting policies that encourage pharmacists and physicians to engage in CDTM, a significant portion of the adult population could have access to pharmacists' clinical services, resulting in improved health outcomes, better health care, and lower costs. Few evidence-based resources exist to educate policy makers about scope of practice laws for chronic disease management. This presentation will describe (1) the current status of state laws regulating the CDTM component of team-based patient care, (2) the barriers, facilitators, and policy factors identified by a consortium of pharmacy stakeholders who have contributed to the implementation of effective collaborative practices, and (3) key policy elements that contribute to successful implementation and sustainability of interdisciplinary care that includes pharmacists.

Learning Areas:
Chronic disease management and prevention
Public health or related laws, regulations, standards, or guidelines
Public health or related public policy

Learning Objectives:
1. Explain the role of pharmacist CDTM policies in chronic disease management. 2. Identify barriers and facilitators to implementing effective CDTM policies. 3. Explain key policy elements for collaborative care that includes the pharmacist.

Keywords: Chronic Diseases, Policy/Policy Development

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have been at the APhA Foundation since 1996, serve as the Vice President for Research, and have been the principle architect for the clinical and technology structure and process models for the Foundation's patient care programs. In this work for a charitable non-profit, I collaborate with pharmacists, physicians, payers, research organizations, and technology companies across the United States to design and implement innovative interdisciplinary care initiatives and health care service delivery models.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.